Literature DB >> 24731446

Inducing a visceral organ to protect a peripheral capillary bed: stabilizing hepatic HIF-1α prevents oxygen-induced retinopathy.

George Hoppe1, Tamara J Lee1, Suzy Yoon1, Minzhong Yu1, Neal S Peachey2, Mary Rayborn1, M Julieta Zutel1, George Trichonas1, John Au1, Jonathan E Sears3.   

Abstract

Activation of hypoxia-inducible factor (HIF) can prevent oxygen-induced retinopathy in rodents. Here we demonstrate that dimethyloxaloylglycine (DMOG)-induced retinovascular protection is dependent on hepatic HIF-1 because mice deficient in liver-specific HIF-1α experience hyperoxia-induced damage even with DMOG treatment, whereas DMOG-treated wild-type mice have 50% less avascular retina (P < 0.0001). Hepatic HIF stabilization protects retinal function because DMOG normalizes the b-wave on electroretinography in wild-type mice. The localization of DMOG action to the liver is further supported by evidence that i) mRNA and protein erythropoietin levels within liver and serum increased in DMOG-treated wild-type animals but are reduced by 60% in liver-specific HIF-1α knockout mice treated with DMOG, ii) triple-positive (Sca1/cKit/VEGFR2), bone-marrow-derived endothelial precursor cells increased twofold in DMOG-treated wild-type mice (P < 0.001) but are unchanged in hepatic HIF-1α knockout mice in response to DMOG, and iii) hepatic luminescence in the luciferase oxygen-dependent degradation domain mouse was induced by subcutaneous and intraperitoneal DMOG. These findings uncover a novel endocrine mechanism for retinovascular protection. Activating HIF in visceral organs such as the liver may be a simple strategy to protect capillary beds in the retina and in other peripheral tissues.
Copyright © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24731446      PMCID: PMC9302206          DOI: 10.1016/j.ajpath.2014.02.017

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   5.770


  40 in total

Review 1.  Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton.

Authors:  Diptiman Chanda; Sanjay Kumar; Selvarangan Ponnazhagan
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

2.  Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture.

Authors:  Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-15       Impact factor: 4.799

3.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Authors:  M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

4.  Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration.

Authors:  Hu Huang; Sara Van de Veire; Mansi Dalal; Rachel Parlier; Richard D Semba; Peter Carmeliet; Stanley A Vinores
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-29       Impact factor: 4.799

5.  Prolyl hydroxylase domain protein 2 (PHD2) mediates oxygen-induced retinopathy in neonatal mice.

Authors:  Li-Juan Duan; Kotaro Takeda; Guo-Hua Fong
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

6.  Erythropoietin deficiency decreases vascular stability in mice.

Authors:  Jing Chen; Kip M Connor; Christopher M Aderman; Lois E H Smith
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

7.  General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.

Authors:  G L Wang; G L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

8.  Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways.

Authors:  Ambreena Siddiq; Leila R Aminova; Carol M Troy; Kyungsun Suh; Zachary Messer; Gregg L Semenza; Rajiv R Ratan
Journal:  J Neurosci       Date:  2009-07-08       Impact factor: 6.167

9.  Erythropoietin regulates endothelial progenitor cells.

Authors:  Ferdinand H Bahlmann; Kirsten De Groot; Jens-Michael Spandau; Aimee L Landry; Barbara Hertel; Thorsten Duckert; Sascha M Boehm; Jan Menne; Hermann Haller; Danilo Fliser
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

10.  NIH Support for the Emergence of Quantitative and Systems Pharmacology.

Authors:  M Rogers; P Lyster; R Okita
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-10
View more
  6 in total

Review 1.  Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders.

Authors:  Yu Chen; Krzysztof Palczewski
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-03-23       Impact factor: 13.820

Review 2.  Neurovascular abnormalities in retinopathy of prematurity and emerging therapies.

Authors:  Chang Dai; Jun Xiao; Chenguang Wang; Wei Li; Guanfang Su
Journal:  J Mol Med (Berl)       Date:  2022-04-08       Impact factor: 5.606

Review 3.  The progress of prophylactic treatment in retinopathy of prematurity.

Authors:  Hong-Bing Zhang; Xiao-Dong Wang; Kun Xu; Xiao-Gang Li
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

4.  Serine and 1-carbon metabolism are required for HIF-mediated protection against retinopathy of prematurity.

Authors:  Charandeep Singh; George Hoppe; Vincent Tran; Leah McCollum; Youstina Bolok; Weilin Song; Amit Sharma; Henri Brunengraber; Jonathan E Sears
Journal:  JCI Insight       Date:  2019-07-25

5.  Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin.

Authors:  Yasir J Sepah; Quan Dong Nguyen; Yusuke Yamaguchi; Tetsuro Otsuka; Yoshikatsu Majikawa; Michael Reusch; Tadao Akizawa
Journal:  Kidney Int Rep       Date:  2022-01-19

6.  Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity.

Authors:  George Hoppe; Suzy Yoon; Banu Gopalan; Alexandria R Savage; Rebecca Brown; Kelsey Case; Amit Vasanji; E Ricky Chan; Randi B Silver; Jonathan E Sears
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.